Effect of mutational status on response, PFS, or OS after treatment with IL-2 for metastatic melanoma.
作者： R. W. Joseph , R. J. Sullivan , D. Panka , G. Manoukian , A. Percy
DOI: 10.1200/JCO.2010.28.15_SUPPL.8597
关键词: In patient 、 Medicine 、 Oncology 、 Internal medicine 、 Mutational status 、 Metastatic melanoma 、 After treatment
摘要: 8597 Background: High dose IL-2 (HD-IL2) is the only FDA-approved treatment that induces durable complete responses (CR) and survival in patients (pts) with metastatic melanoma (MM), but it does so...
sci-hub.st 参考文章(0)